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ABSTRACT  26 
Background: 27 
Evidence is required to quantify the potential risks of transmission of variant 28 
Creutzfeldt Jakob (vCJD) through dental procedures. Studies, using animal 29 
models relevant to vCJD, were performed to address two questions. Firstly, 30 
whether oral tissues could become infectious following dietary exposure to 31 
BSE?  Secondly, would a vCJD-contaminated dental instrument be able to 32 
transmit disease to another patient?  33 
 34 
Methods: 35 
BSE-301V was used as a clinically relevant model for vCJD. VM-mice were 36 
challenged by injection of infected brain homogenate into the small intestine 37 
(Q1) or by five minute contact between a deliberately-contaminated dental file 38 
and the gingival margin (Q2). Ten tissues were collected from groups of 39 
challenged mice at three or four weekly intervals, respectively. Each tissue 40 
was pooled, homogenised and bioassayed in indicator mice.  41 
 42 
Findings:  43 
Challenge via the small intestine gave a transmission rate of 100% (mean 44 
incubation 157±17 days). Infectivity was found in both dental pulp and the 45 
gingival margin within 3 weeks of challenge and was observed in all tissues 46 
tested within the oral cavity before the appearance of clinical symptoms. 47 
Following exposure to deliberately contaminated dental files, 97% of mice 48 
developed clinical disease (mean incubation 234±33 days).  49 
 50 
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Interpretation:  51 
Infectivity was higher than expected, in a wider range of oral tissues, than was 52 
allowed for in previous risk assessments. Disease was transmitted following 53 
transient exposure of the gingiva to a contaminated dental file. These 54 
observations provide evidence that dental procedures could be a route of 55 
cross-infection for vCJD and support the enforcement of single-use for certain 56 
dental instruments.  57 
 58 
Funding: The study was funded by the Department of Health (England); 59 
Contract number 007/0099 60 
61 
vCJD and dental practice 
 4
 INTRODUCTION  62 
vCJD remains a challenge for public health due to uncertain prevalence in the 63 
population and the possibility of cross-infection through medical procedures. 64 
The disease almost certainly emerged due to the consumption of bovine 65 
spongiform encephalopathy (BSE)-infected meat [1] but clinical cases have 66 
not reflected the widespread exposure of the UK population. The possibility of 67 
a self-sustaining and potentially amplifying “epidemic”, caused by the 68 
iatrogenic transmission of vCJD from pre-symptomatic cases and 69 
asymptomatic carriers to more genetically susceptible individuals, is a major 70 
concern.   71 
 72 
The prevalence of the disease in the population is estimated at between 237 73 
and 109 vCJD carriers per million of the UK population (95% confidence limits 74 
49-692 per million [2] and 3-608 per million [3], respectively) All clinical cases 75 
of vCJD, to date, have been PRNP-129 Met homozygotes, but pre-/sub-76 
clinical carriage has been identified in 2 valine homozygotes and a 77 
heterozygous patient [2][4][5]. Extended asymptomatic incubation periods in 78 
these genotypes have been suggested by transgenic animal studies [6] and 79 
also by studies on Kuru [7]. A recent study has identified a patient with 80 
atypical sporadic CJD and valine homozygous at PRNP codon 129 [8] which 81 
could represent the first case of clinical disease in this genogroup. Aside from 82 
blood transfusion [5,9] there remains no evidence of iatrogenic vCJD 83 
transmission to date via any surgical route.  84 
 85 
The potential transmission of vCJD by dental practice remain poorly defined. 86 
A risk assessment carried out by the Department of Health in 2004 87 
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(http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publica88 
tionsPolicyAndGuidance/DH_4084662 ; last accessed 12th November 89 
2011) , suggested a low level of risk, based on the assumption that there 90 
would be insignificant levels of infectivity except within the dental pulp and 91 
that only dental instruments which contacted this material posed any risk of 92 
cross infection. These assumptions are tested in this study.  This risk 93 
assessment was revised in 2007 94 
(http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsP95 
olicyAndGuidance/DH_081170; last accessed 12th November 2011), based 96 
on data which includes the preliminary outputs of this study.  97 
 98 
Studies have described the presence of infectivity in hamsters following 99 
intraperitoneal challenge with 263K scrapie [10], with 7.2 (gingiva) and 5.6 100 
(dental pulp) log LD50 i.c. units (the dose capable of causing the death of 50% 101 
of challenged animals when injected intracranially into hamsters) per gram of 102 
tissue. The study also showed that scrapie could be transmitted through 103 
injection into the dental pulp. A recent study has shown infectivity in the root 104 
of the right caudal incisor tooth in an ME7-scrapie infected mouse following 105 
intracerebral challenge [11]. Collectively these studies suggest the potential 106 
for transmission of the disease via the oral cavity, but comprehensive data, 107 
particularly using prion strains more directly relevant to modelling vCJD in 108 
humans, remains lacking.  109 
 110 
Bioassays using tissues from vCJD patients are underway (HPA 111 
unpublished), but no disease-associated prion protein (PrPSc) staining has 112 
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been observed in any oral tissue from vCJD patients [12].  With very small 113 
number of samples involved and the absence of direct transmission from 114 
human tissue to animals in low titre vCJD tissues (<103 ID/gram tissue; [13]), 115 
rodent-passaged TSE strains are essential to assess the relative levels of 116 
infectivity in different tissues, following exposure by different routes, as well as 117 
data on spread of disease.  118 
 119 
The present study provides evidence on the potential risks of vCJD 120 
transmission by measuring relative levels of infectivity in oral tissues and 121 
assessing the potential for transmission through contact of a contaminated 122 
instrument with the gingival margin.  123 
 124 
METHODS 125 
Primary challenge of VM mice via the small intestine 126 
All studies were conducted under a project license approved by the UK Home 127 
Office.  Prior to submission for approval the license was reviewed by the 128 
Microbiological Services Porton Ethical review committee and signed off by 129 
the Establishment Certificate Holder. Project license 30/2700 was granted by 130 
the UK Home Office under the Animals (Scientific Procedures) Act, 1986. A 131 
volume of 100ȝl of a 2% (w/v) titred stock of BSE301V-infectious mouse brain 132 
homogenate (estimated titre 108.9 infectious units per gram brain) [14] was 133 
injected into the lumen of the upper small intestine. Groups of 10 VM mice (8-134 
10 weeks old) were anaesthetised by intraperitoneal injection of a mixture of 135 
Hypnorm (fentanyl/fluoanisone) and Hypnovel (midazolam) (Schering-Plough 136 
Animal Health, Welwyn Garden City, UK). With the animal in dorsal 137 
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recumbency, a small incision was made in the skin of the upper abdomen, the 138 
upper loop of the jejunum just posterior to the duodenum was visualised and 139 
an injection made through the mesenteric membrane using a 1ml syringe with 140 
a 30G needle. Groups of 10 mice were sacrificed at 3-weekly intervals (3 to 141 
21 weeks) post-inoculation (p.i.) or on appearance of defined clinical 142 
symptoms at around 22-24 weeks [14].  143 
 144 
Primary challenge of VM mice via transient exposure of the gingival 145 
margin.  146 
Dental files were selected to perform the study, due to their relatively small 147 
size and ease of handling. Size “08” (21mm) dental files were immersed in 148 
10% brain homogenate and incubated for 30 minutes. Files were removed, 149 
and air dried at room temperature for 1 hour.  150 
 151 
The mice were fully anaesthetized, as above, and the infected dental file was 152 
gently inserted into the mouth of the mouse in parallel with the right jawbone 153 
at the height of the gingival margin.  It is highly likely that the far point of the 154 
file (up to a maximum of 1mm will have entered the outer layer of the gingival 155 
epithelium (but not the area known as the gingival sulcular 156 
epithelium adjacent to the tooth socket).  Due to the parallel placement, this 157 
penetration would have been at a very glancing angle to the tissue and the 158 
majority of the file was thus left lying in parallel contact with the gingiva along 159 
the length of the jaw (jaw about 6 to 7mm length; contact region with file 160 
estimated at around 5mm) for the designated 5 minute period, after which it 161 
was gently withdrawn. Due to the serrated nature of these files damage to the 162 
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epithelium cannot be ruled out, but on no occasion was there any trauma or 163 
bleeding observed during or after this procedure so any damage to the 164 
epithelium will have been minimal.   165 
 166 
The maximum load of infectivity on coated dental files was estimated. The 167 
dental files are manufactured as a morse taper with an end diameter of 168 
0.08mm. Assuming a 5mm section was inserted into the mouth, the maximum 169 
diameter would be around 0.18mm. Surface area of a plain wire would be 170 
approximately 2mm2 (2ʌ(rav)h + ʌrend2). The fluting is assumed to increase the 171 
area by no more than 5 fold (maximum surface area 10 mm2). Previous 172 
studies using a similar coating strategy have suggested retention of 173 
approximately 0.2µg brain tissue per mm2 [15].  Based on a titre of 108.9 ID50 174 
per gram brain [14] the maximum load of infectivity on the dental file is 175 
estimated at 4x102.9 ID50 per challenge).  176 
 177 
Groups of 10 mice were sacrificed at 4-weekly intervals (1-6 months) post-178 
inoculation (p.i.) or on appearance of defined clinical symptoms [14].  179 
 180 
Analysis of time-course samples 181 
The whole brain (including the medulla oblongata), spleen, salivary gland, 182 
trigeminal ganglia, dental pulp, gingival margin, lingual muscle (front 2/3rds of 183 
the tongue), lingual tonsil (back 1/3 of tongue including tonsular tissue), 184 
salivary gland (submandibular) and saliva (following pilocarpine stimulation) 185 
were collected from mice at the different time points. The individual tissues 186 
from each time point were pooled and stored at -80ºC prior to re-inoculation. 187 
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Tissue homogenates were prepared at 20% (w/v) tissue in phosphate 188 
buffered saline using a Ribolyser (Fast prep 120A; Q-Biogene). As the weight 189 
of tissue from the dental pulp could not be measured this tissue was diluted to 190 
the minimum volume of homogenate required for re-inoculation. Ribolyser 191 
beads were washed with 100ȝl PBS, which was used to dilute the 192 
homogenates to 10% (w/v) prior to inoculation.  193 
 194 
In vivo analysis.  195 
The infectivity of the tissues was assessed by i.c. inoculation into the brains of 196 
VM mice. Groups of 6 VM mice (6-8 weeks old) were anaesthetised by intra-197 
peritoneal injection with alfaxalone/alfadolone (Saffan, Schering-Plough 198 
Animal Health, Welwyn Garden City, UK) and inoculated intra-cranially with 199 
20ȝl of the 10% homogenate. Non-specific toxicity was observed in some 200 
groups and samples were diluted (to 1% or 0.1%) as required.  201 
 202 
Mice were monitored for clinical symptoms and sacrificed by injection of 203 
barbiturate (pentabarbitone sodium) at a defined clinical end-point. Brains 204 
from indicator mice were removed and stored in formalin prior to histological 205 
assessment by Animal Health and Veterinary Laboratories Agency, 206 
Weybridge, UK.  207 
 208 
In vitro analysis 209 
Homogenates were analysed by Western blot essentially as described 210 
previously [14]. In brief, homogenates were digested with Proteinase-K at a 211 
final concentration of 5.37 ȝg/ml for 30 minutes at 60oC.  The enzyme was 212 
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inactivated by incubation with 5mM APMSF (Sigma, Gillingham, UK) in Nu-213 
Page™ gel loading buffer (Invitrogen, Paisley, UK) at 99qC for 10 minutes.  214 
Samples, together with the relevant controls, were run on 4-12% Bis Tris 215 
NuPage gels (Invitrogen, Paisley, UK) and transferred to nitrocellulose. The 216 
membrane was blocked in 5% skimmed milk powder in phosphate buffered 217 
saline containing 0.1% Tween 20 (PBS-T) for 30 minutes, washed in PBS-T 218 
and incubated with primary antibody 6H4 (Prionics, Schlieren, Switzerland) (at 219 
1:10,000 dilution) for 18 hrs at 4oC.  The membrane was washed four times in 220 
PBS-T and bound antibody was detected with anti-mouse horse radish 221 
peroxidase (HRP)-conjugate (Sigma, Gillingham, UK); diluted 1:1000). Signal 222 
was generated using West Dura reagent (Pierce, Cramlington, UK) and 223 
imaged using a Chemidoc image analyser (Pharmacia, Sandwich, UK). The 224 
Western blot method could not detect signal below a gel loading equivalent to 225 
a 0.1% brain homogenate (results not shown).  226 
 227 
 228 
Role of the funding source: 229 
The study was funded by The Department of Health (England) under contract 230 
number 007/0099. The funders had no role in study design, data collection 231 
and analysis, decision to publish or preparation of the manuscript. The 232 
funding body were invited to comment on the manuscript and this resulted in 233 
minor changes to the text of the document. 234 
 235 
The authors were not paid to write the manuscript other than through salary 236 
support as part of the grant awarded.  237 
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 238 
The contributing author had full access to all the data generated as part of the 239 
study and made the final decision to submit the manuscript for publication. 240 
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RESULTS  241 
Primary transmission of infectivity from the small intestine to simulate 242 
oral exposure to BSE. 243 
Mice were challenged via direct inoculation into the small intestine to avoid 244 
any chance of contamination of the oral tissues during the primary challenge. 245 
Disease transmission was observed in all animals, with a mean incubation 246 
period to a defined clinical endpoint of 157 ± 17 days (Table 1A). Previous 247 
studies have shown that direct i.c. challenge with the same titre of infectious 248 
BSE-301V stock (estimated titre 108.9 infectious units per gram brain [14]) 249 
reaches a clinical end-point in 120 ± 8.5 days.  250 
 251 
Analysis of relative levels of infectivity in oral tissues following 252 
simulated oral exposure.   253 
The levels of infectivity in different oral and control tissues were assessed by 254 
re-inoculation of 10% (w/v) tissue homogenate, intracranially into VM mice. 255 
The mean incubation period was compared to a titration series generated 256 
from BSE-301V terminal brain material as reported previously [14]. It is 257 
assumed in this study that serial dilution of infectivity would be unaffected by 258 
the tissue type and as such the incubation period can be used as an 259 
indication of the relative titre in the different tissues. In all cases shorter 260 
incubation to clinical symptoms is indicative of higher titre.  261 
 262 
The study aimed to demonstrate the relative maximum levels of infectivity in 263 
different oral tissues following simulated food-borne exposure to BSE 264 
contamination. All tissues/fluids at the terminal stage of disease showed the 265 
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presence of infectivity (Table 2). In all tissues except for the lingual tonsil, 266 
terminal tissues showed the maximal levels of infectivity recorded for that 267 
tissue. Incubation periods ranged from 118 days (± 0 days, 2/2 animals 268 
infected) for brain tissue through to 213 days (± 33 days, 4/5 animals infected) 269 
for lingual muscle tissue. In the case of lingual tonsil, the shortest incubation 270 
period (197 ± 26 days) and highest attack rate (5/5) was reached by the 15 271 
week time point. The lingual tonsil material from terminal animals showed 272 
lower levels of infectivity with only a single animal (1/6) succumbing to 273 
disease with an incubation of 222 days. 274 
 275 
The oral tissues most likely to be contacted during routine dental surgery, 276 
(gingival margin and dental pulp), gave mean incubation periods of 152 days 277 
(± 0 days, 6/6 animals challenged) and 160 days (± 55 days, 6/6 animals 278 
challenged), respectively. To provide a comparison of the relative levels of 279 
infectivity,  titrated brain samples gave mean incubation periods of 141±11 280 
day (~1000 ID50/milligram), 157±18.5 (~100 ID50/milligram) and 226±94 days 281 
(~10 ID50/milligram) ([14]). This suggests that gingival margin has between 282 
100 and 1000 ID50/milligram, whilst dental pulp is at least 10 to 100 283 
ID50/milligram given that the homogenate was less than 10% (w/v).  284 
 285 
Maximal levels of infectivity were observed in all time course tissues, other 286 
than saliva, ahead of the appearance of any clinical symptoms. Maximal 287 
levels were reached by week 3 (spleen), 9, (salivary gland), 12 (brain, dental 288 
pulp, lingual tonsil), 15 (trigeminal ganglia, lingual muscle, alveolar bone), 18 289 
(gingival margin), respectively. Clinical symptoms appeared around week 22, 290 
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with these animals collected as the terminally diseased group. Saliva from 291 
terminal animals was the only time point which showed infectivity for this 292 
sample (mean incubation 207±44 days; 4/6 animal diseased). 293 
 294 
By the first time-point at 3 weeks post-challenge, infectivity was already 295 
detected in the brain, spleen, trigeminal ganglia, gingival margin, dental pulp, 296 
salivary gland, alveolar bone, and lingual tonsil (with synulox), but not in 297 
lingual muscle or saliva. Incubation periods ranged from 129 days (±2 days; 298 
attack rate 4/4 animals) for spleen to 273 days (1/5 animals) for gingival 299 
margin (Table 2). The incubation period in the spleen sample was already at 300 
the minimum level, corresponding to a maximum level of infectivity for this 301 
tissue. By contrast brain tissue showed a mean incubation period of 233 days 302 
with only 1 of 3 mice that survived challenge developing disease.  303 
 304 
Brain samples were also analysed by Western blot using antibody 6H4 305 
following proteinase K digestion of the 10% homogenates (Figure 1). In 306 
contrast to the bioassay results, levels of detectable PrPres varied significantly 307 
with the conventional triple glycoform banding pattern being observable in the 308 
12 week brain samples only with extended exposure (results not shown) and 309 
increasing in the 15, 18 and 21 week samples to reach maximal levels only in 310 
the terminal group.  311 
 312 
 313 
Transmission of infectivity from the gingival margin following transient 314 
exposure.  315 
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Dental files were used to assess whether short term contact was able to 316 
transmit infectivity via the gingival margin. The exposure was designed to 317 
mimic relatively atraumatic contact between a contaminated dental instrument 318 
and gingival epithelium (although limited abrasion of the gingival epithelium 319 
cannot be excluded – see materials and methods). The dental files were 320 
coated in 10% (w/v) brain homogenate to provide a worse case challenge via 321 
this route and in the absence of prior data on levels of infectivity in oral 322 
tissues.  323 
 324 
Transmission via this challenge route was shown to be efficient with 97.1% 325 
(68/70) of challenged animals succumbing to disease. When the incubation 326 
period of individual animals was plotted (Figure 2A and B), two distinct 327 
incubation-period groups were identified (Paired T-test; p< 0.001). The mean 328 
incubations for these two populations are shown separately in table 1B. The 329 
“early” terminal group had a mean incubation period of 166±18 days (n=11; 330 
range 140-188) whilst the “standard” terminal group had a mean incubation 331 
period of 247±14 days (n=57; range 211-275).  332 
 333 
 334 
Relative levels of infectivity in early and standard terminal groups, 335 
resulting from challenge via the gingival margin.  336 
 337 
The tissues from early and standard terminal groups were collected and 338 
processed as separate groups for re-inoculation into indicator mice (Table 3). 339 
The groups showed similar incubation periods in most tissues. Only alveolar 340 
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bone (174 ±6 days, 6/6 animals challenged vs 160 ±5 days, 6/6 animals 341 
challenged) did not show overlapping standard deviations for early vs 342 
standard terminal groups, respectively. Comparisons were not made where 343 
there were less than 3 surviving animals in each challenged group (lingual 344 
muscle, saliva and gingival margin).  345 
 346 
Analysis of relative levels of infectivity in oral tissues following transient 347 
challenge via the gingival margin. 348 
Levels of infectivity were assessed as described above. Again, all tissues at 349 
the terminal stage of disease showed the presence of infectivity (Table 3). 350 
Incubation periods ranged from 126 days (+/- 5 days, 6/6 animals challenged) 351 
for brain material to 198 days (+/- 43 days, 3/5 animals challenged) for lingual 352 
tonsil, with all tissues showing maximal levels of infectivity in terminal animals. 353 
Saliva again showed infectivity only in terminally diseased animals (160 days, 354 
1/2 animals challenged) and in a single animal at the earliest time point at 355 
extended incubation (353 days, 1/5 animals challenged) possibly due to 356 
persistence of the original inoculum.  357 
 358 
Maximal levels of infectivity were again reached for all tissues (except for 359 
saliva) well ahead of the presentation of clinical symptoms by 4 months (brain 360 
and dental pulp) and 5 months (for all remaining tissues).  361 
 362 
By the first time point in the time course, infectivity was detected in spleen, 363 
gingival margin, lingual muscle, dental pulp, salivary gland, lingual tonsil and 364 
alveolar bone, but not in brain, saliva or trigeminal ganglia. Incubation periods 365 
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ranged from 181 days (+/- 13 days, 6/6 animals challenged) for salivary gland 366 
to 314 days (+/- 116 days, 3/6 animals challenged) for gingival margin. In 367 
several cases, notably in alveolar bone, lingual tonsil and gingival margin, 368 
infectivity was not observed in the 2 month time-point, nor in the 3 month 369 
time-point for gingival margin and lingual tonsil. This again may suggest 370 
localised persistence of the inoculum followed by clearance and later 371 
infiltration.  372 
 373 
Comparison of relative levels of infectivity between terminal groups 374 
challenged by the small intestine or gingival margin. 375 
The relative levels of infectivity were compared between terminally diseased 376 
animals from the two different challenge routes. Only the trigeminal ganglia 377 
(mean incubation 136+/-17 days, 4/4 for small intestine route vs 160 +/-4 378 
days, 6/6 for the gingival challenge route (standard terminal group) and 159 379 
+/- 6 6/6 (early terminal group) did not show overlapping standard deviations. 380 
The lingual muscle samples were statistically different in the early terminal 381 
group from the gingival challenge route when compared to the small intestine 382 
challenge route (too few animals survived in the standard terminal group for 383 
valid comparisons to be made).  Comparisons were not made where there 384 
were less than 3 surviving animals in each group (saliva and gingival margin 385 
in addition to the lingual muscle standard group).  386 
 387 
At earlier time points accumulation of infectivity was proportionally slower in 388 
spleen and trigeminal ganglia than in the gingival challenge route. Spleen in 389 
particular showed much slower accumulation of maximal levels of infectivity, 390 
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reached by week 3 in the small intestine challenge but not until month 5 in the 391 
gingival challenge group.  392 
 393 
394 
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Discussion 395 
The principle aim of the study was to provide underpinning information 396 
regarding the potential risks of vCJD transmission by dental procedures, 397 
which would contribute to a revised dental risk assessment. The data provide 398 
an important insight into potential risks, albeit in a small animal model and 399 
using a worse-case approach.  400 
 401 
The data presented here adds considerable information to the previous 402 
studies related to dental transmission [10-12]. The levels of infectivity 403 
observed in this study are lower than those seen in the Ingrosso study [10]. 404 
There are a number of potential reasons for this difference including; the 405 
challenge route used (intraperitoneal vs direct introduction to the small 406 
intestine), the higher end titre of scrapie vs the BSE agent (typically 1011ID50 407 
per gram brain for 263K Scrapie compared to ~109 ID50 for BSE-301V) and 408 
the different nature of the two prion agents themselves. As BSE-301V is 409 
derived from the same prion agent that caused vCJD in humans, it could be 410 
argued that the lower values are more representative of the levels of infectivity 411 
that might be encountered in dental patients. The absence of detectable 412 
disease-associated prion protein (PrPSc) in human vCJD dental tissues [12] is 413 
not incompatible with the levels of infectivity observed in this study, given that 414 
the bioassay model is considered to be 100-1000 fold more sensitive than 415 
even the high sensitivity Western Blot model used in the Head study. The re-416 
infection studies carried out here are also more representative of the routine 417 
risks of disease transmission during dental procedures, than the highly 418 
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invasive procedure used previously [10], where infectious brain material was 419 
injected directly into the pulp cavity. 420 
 421 
The transmission of infectivity following direct inoculation into the small 422 
intestine proved to be highly efficient. This novel route of challenge probably 423 
accesses the same routes of infection that would be encountered after oral 424 
uptake of infectious material but without the significant reduction in titre (of the 425 
order of 2-3 log) expected on passage through the stomach. Whilst the 426 
approach will inevitably result in localised trauma at the incision site, the 427 
incubation period suggests that leakage into the peritoneum was not the 428 
primary route of infection as intraperitoneal challenge has resulted in animals 429 
reaching their clinical end-point at 196 days [16] with oral challenge at 245 430 
days (unpublished; referenced in  431 
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/do432 
cuments/digitalasset/dh_081219.pdf (last accessed 12th November 2011)). 433 
Rapid accumulation of infectivity in the spleen, reaching maximal levels by the 434 
three week time-point, provides evidence of efficient infection through the 435 
small intestine.  436 
 437 
The observed levels of infectivity, as estimated from incubation period, are 438 
higher than would have been expected in many tissues within the oral cavity. 439 
The two tissues most likely to be relevant to understanding the risks of 440 
iatrogenic dental transmission, the gingival margin and dental pulp, show 441 
levels of infectivity of between 100-1000 and at least 10-100 infectious doses 442 
(ID) per mg tissue, respectively (based on the titration series for brain material 443 
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shown in [14]). The maximal levels of infectivity were reached well ahead of 444 
the presentation of clinical symptoms in the majority of tissues. This is likely to 445 
be similar in the human situation.   446 
 447 
At the outset of the study, there was no indication in the literature that the two 448 
routes of infection would be as efficient as they proved to be. As such the 449 
study used a high challenge dose in order to be able to draw conclusions as 450 
to the spread of infection and accumulation of high levels of infectivity under 451 
worst-case conditions. Despite this, we do not believe that the use of a high 452 
challenge dose, distorts the key findings of the study. In the small intestine 453 
challenge experiments, the levels of infectivity in oral tissues are actually 454 
lower than the levels observed in the one limited but comparable study [10]. 455 
The accumulation of infectivity in the spleen is comparable to the rate seen in 456 
other peripheral challenges (ip and oral) using the same model. The ability of 457 
the spleen to amplify infectivity from low-dose oral or peripheral challenge 458 
suggests that similar levels of infectivity would have been reached in the oral 459 
tissues even with a lower challenge. The different levels of infectivity and the 460 
different rate of accumulation of infectivity in different tissues also suggests 461 
that the model is not simply saturated with infectivity, but rather that it 462 
represents normal spread of infectivity from the intestine, potentially via both 463 
lymphoreticular and direct neuronal transmission.  464 
 465 
Relative levels of infectivity in vivo and PrPSc-signal detectable in vitro.  466 
 467 
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The presence of maximal levels of infectivity in the brain in mice at 12 weeks 468 
is a reminder of the long pre-symptomatic phase of TSE infection. The earliest 469 
clinical symptoms were evident at 18 weeks post-exposure with an average of 470 
22 weeks. The 10-fold dilution data for the 15, 21 and terminal groups, 471 
although limited in nature, suggest that the levels of infectivity reach a 472 
maximal level and are maintained over this period, rather than continuing to 473 
accumulate in the brain. The observed differences in the level of abnormal 474 
prion protein, PrPSc, in the same time-course samples indicates a marked 475 
separation between the level of infectivity and the detected level of its 476 
surrogate marker as observed in previous studies [17, 18].  This may indicate 477 
that an equilibrium is reached for the most infectious form of the agent (e.g. 478 
the 14-28 unit prion protein oligomers [19]) and that this remains unaltered 479 
despite the ongoing accumulation of Proteinase K-resistant aggregated 480 
PrPres. Alternatively, the overall level of infectivity may remain approximately 481 
constant since the capacity to act as individual nuclei of infection diminishes 482 
proportionately to the increasing extent of PrPres aggregation.  Neither 483 
hypothesis was tested in the current study.  484 
 485 
The transient exposure of the gingival margin to infectivity dried onto dental 486 
files demonstrates the potential for iatrogenic transmission of infectivity 487 
through contaminated dental instrument contact within the oral cavity. The 488 
challenge was designed to be less invasive than previous oral inoculations 489 
[10] and gingival scarification [21]. Given the relatively atraumatic instrument 490 
contact, the efficiency of transmission was greater than expected with >97% 491 
of challenged animals succumbing to disease, with a total population mean of 492 
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233 days. The identification of two sub-populations within the culled animals 493 
on the basis of incubation period is intriguing. One of these populations could 494 
represent animals infected by ingestion of material following oral exposure. 495 
However, the use of a low challenge titre dried onto the file (estimated at 496 
around 4x102.9 ID per file) and given the incubation period observed for much 497 
higher challenges via the oral route (245 days; see above), would suggest 498 
that ingestion is not the major infection route. The rapidly progressing (early) 499 
disease may be a result of localised trauma to the gingiva, providing more 500 
efficient spread of the disease, or may indicate that localised uptake has 501 
accessed different infection routes, perhaps mediated by neuronal (early 502 
terminal) and/or lymphatic (standard terminal) tissues, respectively. The 503 
relatively rich neurological innervations of the oral cavity and links with the 504 
trigeminal nucleus in the brain stem may contribute to this rapid route of 505 
spread. Despite the significant differences in the incubation period of animals 506 
identified as early or standard terminal groups, widespread differences in the 507 
levels of infectivity in tissues were not observed on re-challenge.  508 
 509 
The gingival challenge route is entirely novel and was designed to ask 510 
specifically whether infectivity could be transmitted via transient contact rather 511 
than direct inoculation [10].  To assess this, and given the very small amounts 512 
of inocula that are carried on the contaminated dental files, a high titre 513 
material was essential in order to test the feasibility of transmission. In terms 514 
of the validity of the model, the absence of infectivity at the 2 month time point 515 
for several tissues, including gingival margin, suggests that infection is not 516 
simply being generally disseminated through the oral cavity. Again this 517 
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suggests that whilst the model is a worst-case the results are not incompatible 518 
with  a natural infection from a contaminated instrument at lower titres. 519 
 520 
Similar levels of infectivity were observed at the end of the two bioassay 521 
studies, with the exception of lingual muscle which was higher in mice 522 
challenged via the gingival challenge route. Comparing the levels of infectivity 523 
at the first point of each time course showed greater dissemination of 524 
infectivity within the oral cavity for the gingival challenged animals.  This might 525 
have been expected with the tissues potentially retaining some of the initial 526 
inocula. This is supported by the subsequent loss of infectivity in three of the 527 
oral tissues by the second time-point, with gingival margin and lingual tonsil 528 
remaining non-infectious at the third monthly time-point. In contrast, organs 529 
which might be indicative of ingestion and systemic spread from the oral 530 
cavity remained less infectious for a greater proportion of the time-course. For 531 
example, the spleen showed only limited transmission and a longer incubation 532 
period following gingival challenge at the first time-point, with levels of 533 
infectivity not reaching those observed following challenge via the small 534 
intestine until the final terminal group. Similarly, neither trigeminal ganglia nor 535 
brain showed infectivity at the first monthly time-point and increased only 536 
gradually over time. The high levels of infectivity in the salivary gland at the 537 
first time-point and increasing through the incubation suggest that infectivity 538 
was concentrated and amplified in this organ rather than being disseminated 539 
from the descending nerves linked to the trigeminal ganglion, the latter 540 
showing lower levels of infectivity throughout the time-course.  541 
 542 
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 543 
Implications for public health.   544 
There is currently no evidence for the transmission of vCJD through any form 545 
of surgical procedure, including dental practice. Proven transmission by blood 546 
transfusion [5,9] suggests that surgical transmission is a potential risk via 547 
procedures that contact either nervous or lymphoid tissue.  For example, 548 
infectivity has been found in the rectum from a vCJD patient (at 0.001% 549 
infectivity of brain), but not for sporadic CJD, demonstrating the broader 550 
distribution of infectivity [22-24]. Together with this observation, the highly 551 
efficient transmission of infection through direct inoculation into the small 552 
intestine in this study, perhaps raise concerns for endoscopic procedures.  553 
 554 
This study uses a well established mouse model and BSE strain (as a 555 
surrogate for vCJD) that has been used previously to investigate risks of 556 
human to human transmission. Taken together, the observations in the 557 
current study provide theoretical grounds for concern in relation to dental 558 
procedures. The levels of infectivity observed in all the oral tissues, notably 559 
gingival margin tissue with up to an estimated 1000 ID per mg of tissue, were 560 
higher than estimated previously.  561 
 562 
A separate component of the study, has assessed the residual protein 563 
contamination on a range of dental instruments after routine cleaning and 564 
disinfection in general dental practice in England [25]). The study showed a 565 
number of instrument types and cleaning procedures where the upper 566 
interquartile range for residual protein was in excess of 100µg. This could 567 
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equate to up to 100 ID per instrument even in the case of the gingival tissue. 568 
Autoclaving has been shown to achieve up to a 3-log inactivation of various 569 
TSE agents [26] although an autoclave designed for the dental market has 570 
recently been investigated and shown to provide only a 2-log inactivation in 571 
the TSE model used here (134°C, 18 minutes; Sutton et al unpublished). 572 
Whilst the combined prion inactivation of multi-stage decontamination 573 
procedures remains to be proven, a dental instrument soiled with infectious 574 
gingival tissue, under this combination of cleaning and autoclaving, would not 575 
leave a significant safety margin.  576 
 577 
The gingival challenge was designed as a worse case scenario, with respect 578 
to the loading of infectious material onto the surface of the dental instrument, 579 
but was not a highly invasive procedure. The procedure resulted in very high 580 
levels of transmission, suggesting that if the titre of the challenge material was 581 
reduced, transmission would still be likely to occur. Even if this was a 582 
relatively rare event, the very large number of dental interventions that take 583 
place and the high number of procedures carried out on younger age groups 584 
(in contrast to most medical surgical procedures) means the risks are not 585 
negligible.  586 
 587 
The study provides evidence to inform the ongoing debate about the control of 588 
potential risks of vCJD transmission in dental practice. Preliminary data from 589 
the study have already been provided to Department of Health as part of their 590 
revision to the dental risk assessment 591 
(http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/do592 
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cuments/digitalasset/dh_081217.pdf; accessed 12th November 2011). A 593 
number of additional control measures have been put in place, including the 594 
recent revision of the Health technical memorandum relating to 595 
decontamination in dental settings in England 596 
(http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsP597 
olicyAndGuidance/DH_109363; accessed 12th November 2011). An emphasis 598 
on universal decontamination methods and single use for difficult to clean 599 
devices would appear to be sensible precautions given the observations 600 
described in this study, which significantly broaden the possible routes of 601 
infection through dental procedures, with wider dissemination of infectivity in 602 
the oral cavity and  transmission by transient exposure.  603 
 604 
.  605 
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Figures and tables: 617 
Table 1A: Summary of primary challenge data for different transmission routes 618 
 619 
Challenge Route Attack rate (number of 
animals succumbing to 
disease / number of animal 
challenged (% attack rate)) 
Mean incubation / days 
post infection ± standard 
deviation  
Small intestine challenge 46/46 (100%) 157 ± 17*
 
Gingival margin challenge 68/70 (97.1%) 233 ± 33.4¶ 
 
* range 131-230 days, median 153 days; 1 mouse died without clinical BSE 620 
symptoms at 422 days post-challenge, with no histological confirmation of 621 
BSE and was excluded from the calculation (otherwise 178 ±67 days). Outlier 622 
at 230 days; otherwise 156 ± 14 range 131-192.  623 
¶ Table 1B: Separate analysis of primary cull data from gingival challenge shows 624 
two populations  625 
 626 
Challenge Route Attack rate (number of 
animals succumbing to 
disease / number of animal 
challenged (% attack rate)) 
Mean incubation / days 
post infection ± standard 
deviation (range). Data for 
TSE positive animals only. 
Gingival margin; Early 
terminal only 
11/11 (100) 166 ± 18 (140-188) 
Gingival margin; Late 
terminal only 
57/59 (96.6%) 247 ± 14 (211-275) 
 627 
 628 
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Table 2: Average incubation periods for VM mice challenged with tissues taken following small intestine challenge. The mean incubation period 629 
(Bold), standard deviation (italics) and attack rate (mice infected / mice challenged) are all shown.  630 
 631 
 632 
 633 
 634 
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Table 3: Average incubation periods for indicator animals challenged with tissues taken following gingival margin challenge of VM mice. The 636 
mean incubation period (Bold), standard deviation (italics) and attack rate (mice infected / mice challenged) are shown for each tissue type taken 637 
through the time course. Based on the frequency distribution, two separate groups of terminal samples were taken and treated separately, termed early 638 
and standard terminal groups.   639 
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Figure legends: 640 
Figure 1: Detectable levels of PrPSc on Western blots do not correlate with 641 
the levels of infectivity.  10% brain homogenates from an uninfected brain 642 
(lane 2) time-course samples week 3, 6, 9, 12, 15, 18, 21 (lane 3-9), and the 643 
terminal sample (lane 10) were digested with proteinase K at 60oC for 10 644 
minutes and assessed by Western blot. The observed signal does not 645 
correspond with the levels of infectivity found in corresponding bioassays for 646 
the week 12-21 post-exposure time-points. 647 
 648 
Figure 2: Comparison of the cull dates for the mice challenged via the 649 
gingival margin. Panel A; Frequency distribution plots show the presence of a 650 
normally distributed population with a mean incubation period of around 250 651 
days plus a small number of animals with significantly shorter incubations 652 
ranging from 140-188 days. Panel B; when these two groups are compared 653 
they show distinct means and distribution and are considered as distinct 654 
populations (p< 0.001).  655 
 656 
 657 
 658 
659 
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Figures: 660 
Figure 1.  661 
 662 
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Figure 2A 665 
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